profit from every $100 of sales.
$0$100
LENZ Therapeutics
$4.11+0.24% today
-84.5% in 1 year
1-year low $3.011-year high $31.94
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What LENZ Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $15.0 million in 2022 to $19.1 million in 2025, with -$82.1 million of profit last year.
SalesProfit
LENZ Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| LENZ Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads LENZ Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 15 | 0 | 0 | 19 | |
| – | – | 0 | 19 | |
| -10 | -72 | -59 | -91 | |
| -10 | -72 | -59 | -91 | |
| -11 | -70 | -50 | -82 | |
| -0.42 | -2.74 | -2.34 | -2.85 | |
| – | – | – | 97.8% | |
| -69.9% | – | – | -477.5% | |
| -72.1% | – | – | -430.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 47 | 70 | 215 | 306 |
| Cash | 44 | 35 | 20 | 25 |
| Total debt | 0 | 0 | 1 | 1 |
| Total liabilities | 71 | 163 | 11 | 22 |
| -24 | -93 | 204 | 284 | |
| 26 | 26 | 21 | 29 | |
| – | – | -22.5% | -25.2% | |
| 44.7% | 75.5% | -24.4% | -28.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4 | -60 | -59 | -69 | |
| 0 | 0 | 0 | 1 | |
| -4 | -60 | -60 | -70 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 6 | 13 |
Valuation
- –
- –
- –
- 1.0×
- 6.8×
- –
- –
- -54.2%
- -63.6%
- 0.0%
Profitability
- 97.8%
- -477.5%
- -430.3%
- -562.1%
- -48.0%
- 113.1%
- -46.8%
- -40.0%
- -48.0%
- 61.2%
Growth
- +8.4%
- –
- −16.9%
- –
- +36.6%
Financial health
- -0.3×
- 0.00
- 0.1%
- –
- 10.40
- 10.26
- 0.08
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 958
Bottom 42%of 889
Bottom 1%of 987
What analysts expect
- Average price target
- $51.67
- Range
- $32.00 – $67.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -1.32 | -1.10 | −20.0% |
| Mar 24, 2026 | -1.16 | -0.91 | −27.5% |
| Nov 5, 2025 | -0.59 | -0.67 | +11.9% |
| Jul 30, 2025 | -0.53 | -0.58 | +8.6% |
| May 7, 2025 | -0.53 | -0.55 | +3.6% |
| Mar 19, 2025 | -0.46 | -0.42 | −9.5% |
| Nov 6, 2024 | -0.38 | -0.47 | +19.1% |
| Aug 14, 2024 | -0.40 | -0.49 | +18.4% |
News
LENZ Therapeutics GAAP EPS of -$0.99 misses by $0.04, revenue of $3.38M misses by $0.82MSeeking Alpha · Oct 28, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
51No pass
Benjamin Graham
71Pass
Philip Fisher
51No pass
Peter Lynch
47No pass
Joel Greenblatt
4No pass
Charlie Munger
59No pass
Terry Smith
61Pass
Questions about LENZ Therapeutics
Is LENZ Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the LENZ Therapeutics AI analysis
What does LENZ Therapeutics do?
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. It is in Biotechnology.
Does LENZ Therapeutics pay a dividend?
No. LENZ Therapeutics does not pay a dividend at the moment.
Is LENZ Therapeutics stock halal?
No. LENZ Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 226% of its market value, at or above the 33% limit. How we check
How has LENZ Therapeutics stock done over the past year?
Down 84.5% over the past twelve months, to $4.11. It traded between $3.01 and $31.94 and is 87.1% below its high.
Who are LENZ Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with LENZ Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.